Management of hematologic and neuropsychiatric side effects in treatment of chronic HCV infection

Journal for Nurse Practitioners

Volumn 2, Issue 1, 2006, Pages 38-45

  Farley, Jason E ^a,b   Dial, David J ^d   Littleton Kearney, Marguerite ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF NURSING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NONE

Author keywords

HCV treatment; Hepatitis C; Symptom management

Indexed keywords

EID: 33644842909     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2005.11.012     Document Type: Article

References (63)

1. I Williams Epidemiology of hepatitis C in the United States Am J Med. 107 6B 1999 2S 9S
2. MP Manns, JG McHutchison, SC Gordon Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965
3. MW Fried, ML Shiffman, R Reddy Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med. 347 2005 975 982
4. T Hassanein, G Cooksley, M Sulkowski The impact of peg-interferon alpha-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C J Hepatol. 40 2003 675 681
5. MP Manns Adherence to combination therapy: influence on sustained virologic response and economic impact Gastroenterol Clin North Am. 33 1 suppl 2004 S11 S24
6. JG McHutchison, M Manns, K Patel Adherence to combination therapy enhances sustained response in genotype I infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
7. D Bernstein, L Kleinman, CM Barker Relationship of health-related quality of life to treatment adherence and sustained viral response in chronic hepatitis C patients Hepatology 35 2002 704 708
8. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consensus and State-of-the-Science Statements; Vol 19, No. 3. Cited 2005 April 20 Available at: http://consensus.nih.gov/cons/116/hepatitis_c_consensus.pdf Accessed October 5, 2005
9. Veterans Administration Treatment Guidelines Cited 2005 May 3 Available at: www.hcvadvocate.org/hepatitis/About_Hepatitis_pdf/1.1_Hepatits_C/ VA%20Treatment%20Recommendations.pdf Accessed October 5, 2005
10. DB Strader, T Wright, DL Thomas, LB Seeff American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171
11. PEG-Intron (peginterferon alpha-2b, recombinant) [package insert] 2005 Schering Corporation Kenilworth, NJ
12. Copegus (ribavirin, USP) [package insert] 2005 Hoffman-LaRoche, Inc Nutley, NJ
13. Pegasys (peginterferon alpha-2a) [package insert] 2004 Hoffmann-LaRoche, Inc Nutley, NJ
14. Rebetron (Rebetol/Intron A) [package insert] 2005 Schering Corporation Kenilworth, NJ
15. BD Lindenbach Complete replication of hepatitis C virus in cell culture Science 309 2005 623 626
16. T Wakita Production of infectious hepatitis C in tissue culture from a cloned viral genome Nat Med. 11 2005 791 796
17. CA Bonjardim Interferons (INFs) are key cytokines in both innate and adaptive antiviral immune responses - and viruses counteract IFN action Microbes Infect 7 2005 569 578
18. CH Yang, W Shi, L Basu Direct association of STAT3 with the IFNAR-1 chain of the human type-1 interferon receptor J Biol Chem. 271 1996 8057 8061
19. E Barnes, M Salio, V Cerundolo Impact of alpha interferon and ribavirin on the function of maturing dendritic cells Antimicrob Agents Chemother. 48 2004 3382 3389
20. JM Curtsinger, JO Valenzuela, P Agarwal, D Lins, MF Mescher Cutting edge: type I IFNs provide a third signal to CD8 T-cells to stimulate clonal expansion and differentiation J Immunol. 174 2005 4465 4469
21. R Dantzer Cytokine-induced sickness behavior: a neuroimmune response to activation of innate immunity Eur J Pharmacol. 500 2004 399 411
22. S Crotty, R Andino Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin Microbes Infect. 80 2002 86 95
23. P Leyssen, J Balzarini, E De Clercq, J Neyts The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase J Virol. 79 2005 1943 1947
24. NM Dixit, JE Layden-Almer, TJ Layden, AS Perelson Modeling how ribavirin improves interferon response rates in hepatitis C virus infection Nature 432 2004 922 924
25. MS Sulkowski, R Wasserman, L Brooks Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection J Viral Hepat. 11 2004 243 250
26. V Balan, D Schwartz, GY Wu Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin Am J Gastroenterol. 100 2005 299 307
27. SJ Hadziyannis, H Sette, TR Morgan Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med. 140 2004 346 355
28. PJ Pockros, ML Shiffman, ER Schiff Epoetin alpha improved quality of life in anemic HCV infected patients receiving combination therapy Hepatology 40 2004 1450 1458
29. DT Dieterich, R Wasserman, N Brau Once weekly epoetin alpha improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon-alpha Am J Gastroenterol. 98 2003 2491 2499
30. NH Afdhal, DT Dieterich, PJ Pockros Epoetin alpha maintains ribavirin dose in HCV infected patients: a prospective, double-blind randomized controlled study Gastroenterology 126 2004 1302 1311
31. MB Streiff, S Mehta, DL Thomas Peripheral blood count abnormalities among patients with hepatitis C in the United States Hepatology 35 2002 947 952
32. A Soza, JE Everhart, MG Ghany Neutropenia during combination therapy of interferon-alpha and ribavirin for chronic hepatitis C Hepatology 36 2002 1273 1279
33. GH Lyman, NM Kuderer, B Djulbegovic Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis Am J Med. 112 2002 406 411
34. A Sanjo, J Satoi, A Ohnishi Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver disease J Gastroenterol Hepatol. 18 2003 638 644
35. CS Wang, WJ Yao, ST Wang Strong association of hepatitis C (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection Clin Infect Dis. 39 2004 790 796
36. EL Lawitz, MJ Hepburn, TJ Casey A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease non-responsive to antiviral therapy Am J Gastroenterol. 99 2004 2359 2364
37. M Maes Major depression and activation of the inflammatory response system Adv Exp Med Biol. 46 1999 25 46
38. BL Hart Biological basis of the behavior of sick animals Neurosci Behav Rev. 12 1988 123 137
39. OJ Schiepers, MC Wichers, M Maes Cytokines and major depression Prog Neuropsychopharmacol Biol Psychiatry 29 2005 201 217
40. H Anisman, Z Merali, MO Poulter, S Hayley Cytokines as a precipitant of depressive illness: animal and human studies Curr Pharm Des. 11 2005 963 972
41. S Hayley, H Anisman Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: neurochemical and molecular substrates Curr Pharm Des. 11 2005 947 962
42. CL Raison, SD Broadwell, AS Borisov Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C Brain Behav Immun. 19 2005 23 27
43. R Glaser, TF Robles, J Sheridan Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults Arch Gen Psychiatry 60 2003 1009 1014
44. M Schaefer, F Schmidt, C Folwaczny Adherence and mental side effects during hepatitis C treatment with interferon-alpha and ribavirin in psychiatric risk groups Hepatology 37 2003 443 451
45. TM Schramm, BR Lawford, GA MacDonald Sertraline treatment of interferon-alpha-induced depressive disorders Med J Aust. 173 2000 359 361
46. OC Gleason, WR Yates, MD Isbell, MA Philipsen An open-labeled trial of citalopram for major depression in patients with hepatitis C J Clin Psychiatry 63 2002 194 198
47. P Hauser, J Khosla, H Aurora A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C Mol Psychiatry 7 2002 942 947
48. MR Kraus, A Schafer, H Faller, H Csef Paroxetine for the treatment of interferon-alpha induced depression in chronic hepatitis C Aliment Pharmacol Therap. 16 2002 1091 1099
49. MR Kraus, A Schafer, O Al-Taie, M Scheurlen Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression J Viral Hepatitis 12 2005 96 100
50. C Maddock, A Baita, MG Orru Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and discussion of biological mechanisms J Psychopharmacol. 18 2004 41 46
51. DL Musselman, DH Lawson, JF Gumnick Paroxetine for the prevention of depression induced by high-dose interferon alpha N Engl J Med. 13 2001 961 966
52. L Capuron, G Neurauter, DL Musselman Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment Biol Psych. 54 2003 906 914
53. P Grossman, L Niemann, S Schmidt, H Walach Mindfulness-based stress reduction and health benefits: a meta-analysis J Psychosom Res. 57 2004 35 43
54. FP Robinson, HL Mathews, L Witek-Janusek Psycho-endocrine-immune response to mindfulness-based stress reduction in individuals infected with HIV: a quasi-experimental study J Altern Complement Med. 9 2003 683 694
55. T Poynard, P Cacoub, V Ratziu Fatigue in patient with chronic hepatitis C J Viral Hepatitis 9 2002 295 303
56. MR Kraus, A Schafer, S Wibmann Neurocognitive changes in patients with hepatitis C receiving interferon alpha-2b and ribavirin Clin Pharmacol Ther. 77 2005 90 100
57. EA Jones Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy [letter] Lancet 354 1999 397
58. BA Smith, JL Neidig, JT Nickel Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults AIDS 15 2001 693 701
59. V Mock, C Frangakis, NE Davidson Exercise manages fatigue during breast cancer treatment: a randomized controlled trial Psychooncology October 14, 2004 Available at: www.interscience.wiley.com Accessed October 5, 2005
60. J Surakka, A Romberg, J Ruutiainen Effects of aerobic and strength exercise on motor fatigue in men and women with multiple sclerosis: a randomized controlled trial Clin Rehab. 18 2004 737 746
61. IJ Hickman, JR Jonsson, JB Prins Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life Gut 53 2004 413 419
62. RC Hilsabeck, TI Hassanein, W Perry Biopsychosocial predictors of fatigue in chronic hepatitis C J Psychosomatic Res. 58 2005 173 178
63. J Nagano, S Nagase, N Sudo, C Kubo Psychosocial stress, personality, and the severity of chronic hepatitis C Psychosomatics 45 2004 100 106